MadhukarHariprasadTrivediMD

Professor and Chief of the Division of Mood Disorders in the Department of Psychiatry at the University of Texas Southwestern Medical Center at Dallas Betty Jo Hay Distinguished Chair in Mental Health

Join to view full profile

Dr. Trivedi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Trivedi's full profile

Already have an account?

Office
5323 Harry Hines Blvd
Dallas, TX 75390
Phone+1 214-648-5555

Education & Training

Henry Ford Health/Henry Ford HospitalResidency, Psychiatry, 1987 - 1990
Baroda Medical CollegeClass of 1981

Certifications & Licensure

TX State Medical License 1992 - 2026
MI State Medical License 1986 - 1990
American Board of Psychiatry and Neurology Psychiatry

Clinical Trials

Assessing Treatment Emergent Suicidal Ideation in Patients With Major Depression Start of enrollment: 2007 Jul 01
Completed
Efficacy Study of a Computer Decision Support System to Treat Depression Start of enrollment: 2005 Mar 01
Completed
Not Applicable
Combining Medications to Enhance Depression Outcomes Start of enrollment: 2008 Mar 01
Completed
Phase 4
Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant Start of enrollment: 2009 Jul 30
Completed
Phase 2
A Comprehensive Intervention for Diabetes and Comorbid Depression in Primary Care Start of enrollment: 2009 Oct 01
Completed
Phase 4
Exercise as a Treatment for Substance Use Disorders Protocol Start of enrollment: 2010 Jun 01
Completed
Not Applicable
Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression Start of enrollment: 2011 Jul 29
Completed
Phase 2
Trial of Low Field Magnetic Stimulation Augmentation of Antidepressant Therapy in Treatment-Resistant Depression Start of enrollment: 2013 Apr 01
Completed
Not Applicable
Gemfibrozil for Nicotine Smoking Cessation Start of enrollment: 2015 Feb 01
Completed
Phase 2
UTSW Depression Cohort: A Longitudinal Study of Depression Start of enrollment: 2016 Feb 01
Completed
Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder Start of enrollment: 2017 May 05
Completed
Phase 3
Rapid Antidepressant Effects of Leucine Start of enrollment: 2017 Mar 09
Terminated
Phase 2
Resilience in Adolescent Development Start of enrollment: 2016 Dec 01
Recruiting
Promoting Enhanced Pharmacotherapy Choice Through Immunomarkers Evaluation in Depression Start of enrollment: 2019 Jul 23
Terminated
Phase 4
Strategies to Enhance Recruitment and Retention of Black Individuals Into Clinical Trials for Substance Use Disorders Start of enrollment: 2022 Apr 01
Recruiting
Roles: Contact, Principal Investigator
Monthly Injectable BUP for MA Use Disorder (MURB) Trial Start of enrollment: 2023 Mar 24
Terminated
Phase 2
Roles: Principal Investigator, Sponsor-Investigator, Contact
Remote Methadone Ingestion Surveillance Trial (RMIST) Start of enrollment: 2024 Jun 15
Not yet recruiting
Not Applicable
Roles: Contact, Principal Investigator
The Longitudinal Study of Stimulant Use Disorder Start of enrollment: 2023 Nov 16
Recruiting
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Pilot evaluation on an adapted tele-behavioral activation to increase physical activity in persons with depression: a single-arm pilot study.
Chad D Rethorst, Joseph M Trombello, Patricia M Chen, Thomas J Carmody, Lynnel C Goodman
BMC Psychology. 2024-11-09
1 citations
Optimizing Antidepressant Efficacy: Generalizable Multimodal Neuroimaging Biomarkers for Prediction of Treatment Response.
Xiaoyu Tong, Kanhao Zhao, Gregory A Fonzo, Hua Xie, Nancy B Carlisle
Medrxiv. 2024-10-08
110 citations
Bupropion and Naltrexone in Methamphetamine Use Disorder
Madhukar H. Trivedi, Robrina Walker, Walter Ling, Adriane M. dela Cruz, Gaurav Sharma
The New England Journal of Medicine. 2021-01-14

Journal Articles

Bupropion and Naltrexone in Methamphetamine Use Disorder
Madhukar H Trivedi, Gavin Bart, Edward V Nunes, Steven Shoptaw, The New England Journal of Medicine
Opioid System Modulation with buprenorphine/samidorphan Combination for Major Depressive Disorder: Two Randomized Controlled Studies
Michael E Thase, Madhukar H Trivedi, Maurizio Fava, Nature
The Concise Health Risk Tracking Self‐Report (CHRT‐SR) Assessment of Suicidality in Depressed Outpatients: A Psychometric Evaluation
Madhukar H Trivedi, Thomas J Carmody, A John Rush, Depression and Anxiety
Double-Blind, Placebo-Controlled, Dose-Ranging Trial of Intravenous Ketamine as Adjunctive Therapy in Treatment-Resistant Depression (TRD)
Sanjay J Mathew, Madhukar H Trivedi, Lee C Chang, Dan V Iosifescu, Manish K Jha, Maurizio Fava, Marlene P Freeman, Cristina Cusin, James Murrough, George I Papakostas,..., Nature
Pretreatment and Early-Treatment Cortical Thickness Is Associated with SSRI Treatment Response in Major Depressive Disorder
Elizabeth A Bartlett, Jie Yang, Benji T Kurian, Madhukar Trivedi, Ramin V Parsey, Myrna Weissman, Maurizio Fava, Joseph M Trombello, Melvin McInnis, Nature
Join now to see all

Authored Content

Review Article Definition of Treatment-Resistant Depression – Asia Pacific PerspectivesNovember 2018
S132. Cerebral Blood Perfusion Predictors of Antidepressant Response in Major Depressive DisorderApril 2018
S131. Resting State Functional Connectivity Patterns Differentially Predict Treatment Outcomes to Sertraline Versus Placebo in Patients with Major Depressive DisorderApril 2018
S132. Cerebral Blood Perfusion Predictors of Antidepressant Response in Major Depressive DisorderApril 2018
S131. Resting State Functional Connectivity Patterns Differentially Predict Treatment Outcomes to Sertraline Versus Placebo in Patients with Major Depressive DisorderApril 2018
Characterizing Anxiety Subtypes and the Relationship to Behavioral Phenotyping in Major Depression: Results from the EMBARC StudyApril 2018
Characterizing Anxiety Subtypes and the Relationship to Behavioral Phenotyping in Major Depression: Results from the EMBARC StudyApril 2018
A Psychometric Evaluation of the Concise Health Risk Tracking Self-Report (CHRT-SR)- a Measure of Suicidality-in Patients with Stimulant Use DisorderMarch 2018
Join now to see all

Press Mentions

UTSW Research: Alcohol-Associated Liver Disease, Depression Treatment, and MoreSeptember 26th, 2024
Deep Brain Stimulation for Parkinson’s Disease: What Is It, Advantages, Side Effects and MoreApril 18th, 2023
New Institute for Brain, Mental Health Research Advances in Texas HouseApril 11th, 2023
Join now to see all

Grant Support

Establishing Moderators/Biosignatures Of Antidepressant Response- Clinical CareNational Institute Of Mental Health2010–2011
Mood Disorders Clincal Intervention Training ProgramNational Institute Of Mental Health2009–2011
A Comprehensive Intervention For Diabetes And Comorbid Depression In Primary CareNational Institute Of Diabetes And Digestive And Kidney Diseases2009–2010
Using Information Technology To Provide Measurement Based Care For Chronic IllnesAgency For Healthcare Research And Quality2007–2009
Revamp Follow-UpNational Institute Of Mental Health2006–2008
Mood Disorders Clinical Intervention Training ProgramNational Institute Of Mental Health2006–2007
Computerized Decision Support System For DepressionNational Institute Of Mental Health2003–2007
Treatment With Exercise Augmentation For DepressionNational Institute Of Mental Health2003–2006
Cbasp Augmentation For Treatment Of Chronic DepressionNational Institute Of Mental Health2002–2005
GABA Neuroendocrine Challenge In Major DepressionNational Center For Research Resources1997
Spect Evaluation Of 5HT1A CNS System In DepressionNational Institute Of Mental Health1995–1996